[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glioblastoma---category\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glioblastoma---category":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100640405","litt-for-ultra-early-gbm-recurrence-100640405",false,"NCT07616986","LITT for Ultra-early GBM Recurrence","Laser Interstitial Thermal Therapy for Ultra-Early, Pre-Radiotherapy Glioblastoma Recurrence","Inclusion Criteria:\n\n* Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status\n* ≥18 years of age\n* CRET\n* Karnofsky Performance Status (KPS) ≥70\n* No contra-indication for radio-chemotherapy\n* Scheduled for adjuvant radio-chemotherapy at University Hospital of Bern\n* Able to provide informed consent\n* No contra-indication for LITT\n* No pregnancy or active breast-feeding\n* No known coagulopathy independent of medication\n* No dissemination or multifocal disease\n* Patients lacking capacity to consent or considered vulnerable (e.g., minors, those under legal protection) are not included.\n\nExclusion Criteria:","ALL","18 Years",{"count":19,"type":20},12,"ESTIMATED","INTERVENTIONAL",[23],"NA","Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT\u002FCT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy.\n\nLITT offers a minimally invasive alternative that may:\n\n* Treat recurrence without delaying RT\u002FCT\n* Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-week window between pre-RT MRI and radiotherapy initiation, maintaining the adjuvant schedule.",[26,27],"Glioblastoma (GBM)","Glioblastoma - Category",[29,30,31,32,33,34],"LITT","Laser Interstitial Thermal Therapy","ultra-early recurrence","GMB","GMB recurrence","GMB ultra-early recurrence","RECRUITING","2026-05-28",{"date":38,"type":39},"2026-06-01","ACTUAL",{"date":41,"type":39},"2026-02-06",{"date":43,"type":20},"2028-01-31",{"name":45,"class":46},"Insel Gruppe AG, University Hospital Bern","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100603309","phase-1-a-study-assessing-if-it-is-safe-and-possible-to-treat-brain-cancer-patients-with-immunotherapy-before-they-receive-the-standard-treatment-100603309","NCT07134842","A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.","Window Studies in Glioblastoma: A Phase I Trial Investigating Neoadjuvant Ipilimumab in Newly Diagnosed Glioblastoma","WinGlio-ipi","Inclusion Criteria:\n\n1. Radiologically or histologically confirmed, newly diagnosed de-novo supratentorial glioblastoma (including gliosarcoma)\n2. Age ≥18 years\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (see appendix 3)\n4. Clinically fit for, and appropriate to receive, neoadjuvant ipilimumab followed by standard of care treatment, based on investigator and MDT judgement\n5. Adequate organ and bone marrow function:\n\n   * Hb ≥9 g\u002FdL\n   * Neutrophils ≥1.5 x 109\u002FL\n   * Platelets ≥100 x 109\u002FL\n   * Lymphocyte count ≥1.0 x 109\u002FL\n6. Adequate renal function:\n\n   • Creatinine clearance of ≥ 50mL\u002Fmin calculated by Cockroft-Gault equation\n7. Adequate liver function:\n\n   * Bilirubin ≤ 1.5 x ULN (except for patients with known Gilbert's Syndrome who may have total bilirubin ≤ 3 x ULN)\n   * Aspartate or alanine transferase (AST or ALT) ≤ 2.5 x ULN\n8. Life expectancy of greater than 12 weeks\n9. Willing to comply with the contraceptive requirements of the trial (see section 6.3.5)\n10. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures\n11. Written informed consent\n\nExclusion Criteria:\n\n1. Known extracranial metastatic or leptomeningeal disease\n2. Prior treatment for glioblastoma other than a biopsy or limited resection leaving residual disease\n3. Dexamethasone dose \\>3mg daily (or equivalent) at the time of starting study treatment\n4. Antibiotics received within 30 days prior to starting study treatment, except for prophylactic antibiotics given with surgery\n5. Intratumoural or peritumoural haemorrhage deemed significant by the treating clinician\n6. Active autoimmune disease apart from:\n\n   1. Skin conditions such as psoriasis, vitiligo or alopecia not requiring systemic treatment\n   2. Type 1 diabetes or thyroid disease, controlled on medication\n7. Any evidence of severe or uncontrolled diseases (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease)\n8. Known hypersensitivity to ipilimumab or any of its excipients\n9. Past medical history of interstitial lung disease, idiopathic pulmonary fibrosis, drug-induced interstitial disease which required steroid treatment or any evidence of clinically active interstitial lung disease.\n10. Any condition requiring systemic treatment with corticosteroids (\\>10mg prednisolone daily or equivalent) or other immunosuppressive medications within 14 days prior to starting study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses \\> 10mg daily prednisolone or equivalent are permitted in the absence of active autoimmune disease.\n11. Treatment with any other investigational agent within 28 days or 5 half lives of the investigational agent (whichever is longer) prior to starting ipilimumab treatment.\n12. History of previous cancer within 5 years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and non-melanoma skin lesions\n13. Positive serology for Hepatitis B defined as a positive test for HepB surface antigen (HBsAg). Note: patients who are HepB core antibody (HBcAb) positive will only be eligible for the study if the HepB virus deocyribonucleic acid (DNA) test is negative and patients are willing to undergo monthly monitoring for HBV reactivation.\n14. Positive serology for Hepatitis C defined as a positive test for HCV antibody\n15. Diagnosis of prior immunodeficiency or organ-transplant requiring immunosuppressive therapy or known HIV or acquired immunodeficiency syndrome (AIDS)-related illness\n16. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\n17. Women who are pregnant or breast feeding",{"count":57,"type":20},16,[59],"PHASE1","WinGlio is a phase I study investigating neoadjuvant (before surgery) ipilimumab ( a type of immunotherapy drug) in patients with newly diagnosed glioblastoma (a form of brain cancer). Participants will receive up to 2 cycles of ipilimumab prior to the standard of care treatments for this patient group which can include debulking surgery and chemoradiation. The aim of giving the ipilimumab to the participants is to see if it is safe to treat patients with this condition with ipilimumab and also to see if the drug helps to reduce or control the patient's disease.",[62,63,27],"Glioblastoma","Gliosarcoma, Adult",[65,66,67,62],"phase 1","immunotherapy","Brain Cancer","2026-04-08",{"date":70,"type":39},"2026-04-09",{"date":72,"type":39},"2025-07-10",{"date":74,"type":20},"2028-01-01",{"name":76,"class":46},"University College, London",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":47},"100625277","clinical-significance-of-liquid-biopsy-in-brain-tumor-patients-a-5-ala-guided-approach-100625277","NCT07420543","Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach","FLUO-LB","Inclusion Criteria:\n\n* Inclusion Criteria (Glioblastoma Patients):\n* Patient aged 18 years or older\n* Diagnosis of supratentorial glioblastoma at its first occurrence (Grade 4, WHO 2021), confirmed through histological analysis, in a brain area that is accessible for surgical removal.\n* Ability of the patient to give informed consent.\n* Suitability for surgery with fluorescence guidance using 5-ALA.\n\nInclusion Criteria (Other Brain Tumors):\n\n* Patient aged 18 years or older\n* Ability of the patient to give informed consent.\n* Suitability for surgery with fluorescence guidance using 5-ALA.\n\nExclusion Criteria:\n\nExclusion Criteria (Glioblastoma Patients):\n\n* Presence of other systemic tumors.\n* Known allergic sensitivity or contraindications to gadolinium.\n* Contraindications to MRI, such as the presence of non-compatible implanted devices.\n* Significantly compromised renal function (eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m²), and\u002For patients undergoing dialysis.\n* Conditions that contraindicate surgery with fluorescence guidance using 5-ALA.\n\nExclusion Criteria (Other Brain Tumors):\n\n* Patients suffering from systemic tumors (besides the primary of the brain metastasis).\n* Individuals with known allergies or adverse reactions to gadolinium.\n* Individuals with contraindications for MRI, including those with implants not compatible with the procedure.\n* Individuals with significantly reduced kidney function (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m²), or those undergoing dialysis.",{"count":85,"type":20},30,"OBSERVATIONAL","Glioblastoma (GBM) is the most common and lethal primary brain tumor. Identifying blood biomarkers that reflect the tumor's status is a major unmet need for optimal clinical management. 5-ALA (5-Aminolevulinic Acid) administration leads to the accumulation of fluorescent Protoporphyrin IX (PpIX) in GBM cells, allowing identification during surgery. This project aims to leverage 5-ALA induced fluorescence to maximize the informational power of plasma liquid biopsy as a tool for diagnosis, post-treatment follow-up, and as a prognostic tool in patients with GBM.",[89,62,26,27],"Brain Tumors and\u002For Solid Tumors Including",[26,62,91,92,93,94,95],"Liquid Biopsy","GBM","5-ALA","Protoporphyrin IX (PpIX)","Fluorescence","2026-02-11",{"date":98,"type":39},"2026-02-19",{"date":100,"type":39},"2017-01-18",{"date":102,"type":20},"2027-05",{"name":104,"class":46},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta"]